Summary
COVID-19 is characterized by vascular inflammation and thrombosis, including elevations in P-selectin, a mediator of inflammation released by endothelial cells. We tested the effect of P-selectin inhibition on biomarkers of thrombosis and inflammation in patients with COVID-19. Hospitalized patients with moderate COVID-19 were randomly assigned to receive either placebo or crizanlizumab, a P-selectin inhibitor, in a double-blind fashion. Crizanlizumab reduced P-selectin levels by 89%. Crizanlizumab increased D-dimer levels by 77% and decreased prothrombin fragment. There were no significant differences between crizanlizumab and placebo for clinical endpoints. Crizanlizumab was well tolerated. Crizanlizumab may induce thrombolysis in the setting of COVID-19. (Crizanlizumab for Treating COVID-19 Vasculopathy [CRITICAL]; NCT04435184)
【저자키워드】 Inflammation, Exocytosis, coronavirus, thrombosis, crizanlizumab, endothelial, 【초록키워드】 COVID-19, Biomarker, P-selectin, Clinical endpoints, endothelial cells, Placebo, inhibitor, D-dimer level, Vasculopathy, double-blind, no significant difference, Elevation, vascular inflammation, Randomly, treating, tested, reduced, characterized, induce, assigned, released, receive, patients with COVID-19, patients with moderate, 【제목키워드】 Effect, P-Selectin Inhibitor,